Related Experiment Video
Updated: Sep 28, 2025

Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
Complete AV Block in Vaccinated COVID-19 Patient
Kevin Lee1, Osman Rahimi1, Neelesh Gupta2
1Department of Internal Medicine, University of Nevada, Las Vegas, 1707 W Charleston Blvd, Suite 100, Las Vegas, NV 89102, USA.
This case study highlights a rare instance of complete atrioventricular block as an initial symptom of Coronavirus 2019 (COVID-19) in an 84-year-old male. Vaccination is emphasized as critical for preventing severe COVID-19 cardiac complications.
Area of Science:
- Cardiology
- Infectious Diseases
- Virology
Background:
- Coronavirus 2019 (COVID-19) emerged in late 2019, initially presenting with respiratory symptoms.
- Cardiac manifestations of COVID-19 are diverse, including arrhythmias and heart failure.
- Vaccination against COVID-19 is a key preventive strategy.
Observation:
- An 84-year-old male, vaccinated against COVID-19, presented with prodromal symptoms and was diagnosed with COVID-19 and complete atrioventricular (AV) block.
- The patient had a history of coronary artery disease, hypertension, and hyperlipidemia.
- Despite transfer to a tertiary center, the patient refused invasive cardiac interventions and was discharged with complete AV block.
Findings:
- This case presents a novel association of complete AV block as an initial symptom of COVID-19 in a vaccinated individual.
- Potential etiologies for the complete AV block include viral myocarditis, COVID-19-induced Takotsubo cardiomyopathy, or direct conduction pathway infection.
- The case underscores the challenges in managing complex cardiac presentations of COVID-19.
Implications:
- Management requires a multidisciplinary approach for patients with COVID-19 and cardiac complications.
- Early recognition and intervention are crucial for improving outcomes in COVID-19 cardiac cases.
- Continued emphasis on COVID-19 vaccination is vital for preventing severe disease and its cardiac sequelae.
More Related Videos
Related Concept Videos
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

